Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-09 5:30 pm Purchase | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 12,543,444 5.700% | 149,877 (+1.21%) | Filing History |
| 2025-02-13 4:31 pm Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 12,393,567 5.800% | 2,497,664 (+25.24%) | Filing History |
| 2024-02-14 4:36 pm Purchase | 2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 9,895,903 5.800% | 1,037,042 (+11.71%) | Filing History |
| 2023-02-13 4:31 pm Purchase | 2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 8,858,861 6.100% | 1,655,613 (+22.98%) | Filing History |
| 2022-02-17 4:12 pm Purchase | 2021-12-31 | 13G | Kronos Bio, Inc. KRON | Arie Belldegrun, M.D. | 3,444,889 6.100% | 3,444,889 (New Position) | Filing History |
| 2022-02-14 3:36 pm Purchase | 2021-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 7,203,248 5.000% | 708,755 (+10.91%) | Filing History |
| 2021-02-12 2:32 pm Sale | 2020-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Arie Belldegrun, M.D. | 6,494,493 4.600% | -859,507 (-11.69%) | Filing History |